Advertisement Fidelity
Home > Boards > US Listed > Biotechs >

Titan Pharmaceuticals (TTNP)

TTNP RSS Feed
Add TTNP Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator Rentier, Truth4Once
Search This Board:
Last Post: 4/18/2014 7:36:46 PM - Followers: 155 - Board type: Free - Posts Today: 0

 

Company Overview

Titan Pharmaceuticals, Inc is a biopharmaceutical company focused in the development of products for the treatment of central nervous system (CNS) diseases. Titan's first out licensed product, Fanapt® (iloperidone) is an atypical antipsychotic approved in the U.S. in May 2009 for the treatment of schizophrenia in adult patients. It is currently marketed in the U.S. by Novartis Pharma, AG, and Titan is entitled to receive 8-10% of global annual sales as royalty revenue for the term of the licensed patents.

 

Titan's second product, Probuphine, is nearing completion of the Phase 3 clinical development program in the treatment of opioid addiction. Probuphine is a novel, subcutaneous implant formulation of buprenorphine designed to deliver six months of medication following single treatment. This product has already demonstrated strong positive results in the first controlled Phase 3 study for the treatment of opioid addiction. The confirmatory Phase 3 study is currently being conducted at 20 sites in the U.S., and the results of this study are expected in Q2, 2011. Additional information on the Probuphine program is available in the PRODUCTS section of this website.

 

The Company's common stock is traded on the OTC Bulletin Board Markets ([TTNP.OB] www.otcbb.com) quotations system. For further information please contact info@titanpharm.com

 

Management Team

Sunil Bhonsle, M.B.A.

President

Katherine L. Beebe, Ph.D.

Executive Vice President and Chief Development Officer

Marc Rubin, M.D.

Executive Chairman



Product Overview

The investigational products are at various stages of development as listed below.

Titan Pharmaceuticals Products

In addition to the potential royalty revenues from iloperidone, Titan is currently focused on adding value to the company from these assets, particularly Probuphine. Additional information on Probuphine and other programs are available in the next sections. If you are interested in learning more, please contact Sunil Bhonsle, President, at sbhonsle@titanpharm.com

 

September 14, 2012 - Titan Pharmaceuticals Announces $4.25 Million Stock Purchase and Option Agreement
Download PDF
August 10, 2012 - Titan Pharmaceuticals Announces Second Quarter 2012 Financial Results
Download PDF
August 8, 2012 - Titan Pharmaceuticals Schedules Conference Call to Review Second Quarter 2012 Financial Results
Download PDF
July 9, 2012 - Titan Completes Preclinical Study of a Continuous, Dopamine Agonist Treatment For Parkinson's Disease
Download PDF
May 11, 2012 - Titan Pharmaceuticals Announces First Quarter 2012 Financial Results
Download PDF
May 9, 2012 - Titan Pharmaceuticals Schedules Conference Call to Review First Quarter 2012 Financial Results
Download PDF
April 20, 2012 - Titan Pharmaceuticals Announces Phase 3 Probuphine®Data Presentation At The American Society Of Addiction Medicine (ASAM) 43Rd Medical-Scientific Conference
Download PDF
April 10, 2012 - Titan Pharmaceuticals to Raise $5.5 Million in Registered Direct Offering
Download PDF
March 16, 2012 - Titan Pharmaceuticals Announces Fourth Quarter and Year-End 2011 Financial Results
Download PDF
March 14, 2012 - Titan Pharmaceuticals Schedules Conference Call to Review Fourth Quarter and Full Year 2011 Financial Results
Download PDF
February 9, 2012 - Titan Pharmaceuticals Announces Positive Results of Six-Month Open-Label Safety Retreatment Study Of Probuphine
Download PDF
February 7, 2012 - Titan Pharmaceuticals to Present at 14th Annual BIO CEO & Investor Conference
Download PDF
PostSubject
#2700  Sticky Note How Will Physicians and Payers Value Advances in Truth4Once 03/19/14 06:35:43 AM
#2794   Wouldn't it be interesting if titan, after they turks 04/18/14 07:36:46 PM
#2793   Rsi is 27.6...not sure how meaningful this metric matthewverymuch 04/15/14 06:19:00 PM
#2792   One word oversold bluejacket6 04/15/14 03:27:40 PM
#2791   Hang in there. Company has a lot of bluejacket6 04/15/14 11:00:54 AM
#2789   Time to truly stay away from the yahoo matthewverymuch 04/14/14 10:39:21 PM
#2788   Matt, it is still or it will be turks 04/14/14 05:40:47 PM
#2787   Do you still think this is "fast tracked"? matthewverymuch 04/12/14 03:41:48 PM
#2785   One word...OTC that is why. Most institutions Rentier 04/09/14 09:54:30 PM
#2784   The fact that titan/braeburn can't even get the matthewverymuch 04/09/14 12:19:12 PM
#2783   Did you listen to the con. call? FDA bluejacket6 04/08/14 06:12:09 PM
#2782   I remember that. Still FDA is sneaky, AntiMarketMaker 04/08/14 05:51:09 PM
#2781   I know, I can't figure out why this bluejacket6 04/08/14 03:51:12 PM
#2780   Though uncommon, many years back I was in bluejacket6 04/08/14 03:45:46 PM
#2779   rays or not rays pizza in brooklyn? James Russler 04/07/14 09:22:59 PM
#2778   i hope we get close to that, in James Russler 04/07/14 09:22:04 PM
#2777   Fair value. $1.50. Let's go. matthewverymuch 04/07/14 01:22:17 PM
#2776   It broke down thru that 40k at .65 hyrpowr 04/07/14 10:36:01 AM
#2775   The average pe ratio of biotech firms is matthewverymuch 04/06/14 07:10:22 PM
#2774   Nice analogy!!! Member mark #1 for you my dbg1969 04/05/14 11:08:57 PM
#2773   Gold standard by 2017 approval by 3rd or turks 04/05/14 10:47:29 PM
#2772   I sold some a few weeks back when dbg1969 04/05/14 07:40:36 PM
#2771   I'm buying at these crazy cheap turks 04/05/14 02:24:45 PM
#2770   Hoping to load more this coming week while dbg1969 04/05/14 01:28:17 PM
#2769   Maybe someone at the FDA who didn't get dbg1969 04/05/14 01:20:36 PM
#2768   I don't think you' ll hear or see turks 04/05/14 12:26:50 PM
#2767   Have not seen any follow up yet on Rentier 04/05/14 10:25:20 AM
#2766   What ever became of that fed raid of matthewverymuch 04/04/14 09:51:58 PM
#2765   You would be correct on both counts. Rentier 04/04/14 09:35:32 PM
#2764   I saw that BS! AntiMarketMaker 04/04/14 05:52:12 PM
#2763   This BS drug got an approval? TTNP AntiMarketMaker 04/04/14 05:49:30 PM
#2762   Titan & Braeburn Prep Next Steps With Probuphine Truth4Once 04/04/14 04:44:25 PM
#2761   HEY my Titan friends check out the article bluejacket6 04/04/14 02:44:35 PM
#2760   The Gold Standard by 2017??? Does that mean dbg1969 04/04/14 02:36:13 AM
#2759   Why the run around?two people told me that turks 04/03/14 02:54:13 PM
#2758   Yeah, the need is definitely there. No doubt matthewverymuch 04/03/14 02:30:09 PM
#2757   Hey mat, I wrote a very interesting email turks 04/03/14 02:07:11 PM
#2756   green here. took seat. lady glueck 04/03/14 01:34:27 PM
#2755   Way ahead of you on that one MVM. Truth4Once 04/03/14 12:29:04 PM
#2754   I wrote a letter to the fda implorimg matthewverymuch 04/03/14 12:21:23 PM
#2753   I like the way you think. :-) Truth4Once 04/03/14 11:57:27 AM
#2752   And, importantly, encouraging the development of medications Truth4Once 04/03/14 11:51:40 AM
#2751   This is actually great news for titan/braeburn , turks 04/03/14 11:48:28 AM
#2750   FDA Commissioner Margaret A. Hamburg Statement on Prescription Truth4Once 04/03/14 11:28:14 AM
#2749   FDA approves new hand-held auto-injector to reverse opioid overdose Truth4Once 04/03/14 11:21:41 AM
#2748   Thanks T40, thats what I thought but when turks 04/03/14 10:41:38 AM
#2747   Details of the study, including size and the Truth4Once 04/03/14 05:02:40 AM
#2746   His predictions are about as good as the Rentier 04/03/14 01:48:20 AM
#2745   What letter are you referring to??? Did I turks 04/02/14 11:15:43 PM
#2744   Napodano's prediction will most likely change again;depending upon Truth4Once 04/02/14 11:07:16 AM
#2743   Napodano pushed potential approval back to 2017!! I matthewverymuch 04/02/14 10:59:07 AM
PostSubject